Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRE Combined With Apalulizumab for Locally Advanced Pancreatic Cancer
NCT07306273Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2025
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in pancreatic adenocarcinoma (PDAC), sponsored by Ruijin Hospital. Started Dec 2025; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07306273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07306273.